GSTM1 and chronic kidney disease: The CREATE trial demonstrated improved QoL without an increased risk of cardiovascular events in adults with CKD randomised to a higher Hb target (13.0–15.0 g/dl) (n = 301), despite >90% of patients having cardiovascular morbidities at baseline.